Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02677116 · ClinicalTrials.gov registry record · Phase 1
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT02677116 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 68 participants.
The verdict
NCT02677116, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has three parts. In the first two parts, a specific dose of olaratumab will be given in 21 day cycles, followed by one of three standard chemotherapy regimens. In the third part, a specific dose of olaratumab will be given with one of three standard chemotherapy regimens in 21 day cycles. Participants will only enroll in one part.
Interventions
- DRUG Doxorubicin
- DRUG Vincristine
- DRUG Irinotecan
- DRUG Ifosfamide
- DRUG Olaratumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2016-08-29 |
| Est. Completion | 2019-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02677116
The ClinicalTrials.gov registry entry for NCT02677116 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT02677116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02677116 about?
NCT02677116 is a clinical study titled "A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer". The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has three par...
What is the current status of trial NCT02677116?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2016-08-29. Estimated completion is 2019-04-03.
What interventions are being tested in trial NCT02677116?
The interventions under investigation include: Doxorubicin (DRUG), Vincristine (DRUG), Irinotecan (DRUG), Ifosfamide (DRUG), Olaratumab (DRUG).
Who is sponsoring clinical trial NCT02677116?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.